AB 928

Drug Profile

AB 928

Alternative Names: A2aR antagonist; AB928

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arcus Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 13 Nov 2017 Phase-I clinical trials in Cancer (In volunteers) (PO)
  • 13 Nov 2017 Arcus plans a phase I/II trial for Cancer (In combination with AB122) in the first half of 2018.
  • 01 Apr 2017 Preclinical trials in Cancer in USA (PO) (Arcus Biosciences pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top